Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zetia/Vytorin Capture 12.5% Share Of New Cholesterol-Lowering Scripts

This article was originally published in The Pink Sheet Daily

Executive Summary

Most of the share gains for the Merck/Schering joint venture are coming at the expense of Pfizer’s Lipitor and Merck’s Zocor, Schering says. Global sales for the joint venture more than doubled to $518 mil. in the second quarter.

You may also be interested in...



Schering In Talks With Potential Partners For HDL Cholesterol Therapy

Schering and Merck’s cholesterol franchise continues to gain growth in terms of market share, but sequential sales of the combination therapy Vytorin fall flat.

Schering In Talks With Potential Partners For HDL Cholesterol Therapy

Schering and Merck’s cholesterol franchise continues to gain growth in terms of market share, but sequential sales of the combination therapy Vytorin fall flat.

Schering To Acquire Full U.S. Marketing Rights To Integrilin From Millennium

Deal will build on Schering’s foundation in cardiovascular care and provide increased flexibility for sale force effectiveness and promotions, the company says. For Millennium, move will provide a revenue stream to support Velcade and products in development.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel